VOR BIOPHARMA INC. - COMMON STOCK

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

23 3 2023 15:01:00 提供 Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

21 2 2023 07:00:01 提供 Nasdaq GlobeNewswire

First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

16 2 2023 11:00:00 提供 Nasdaq GlobeNewswire

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

19 1 2023 07:00:00 提供 Nasdaq GlobeNewswire

Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference

12 1 2023 07:00:00 提供 Nasdaq GlobeNewswire

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

07 12 2022 06:45:00 提供 Nasdaq GlobeNewswire

First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

07 12 2022 06:30:00 提供 Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

22 11 2022 07:00:02 提供 Nasdaq GlobeNewswire

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

10 11 2022 15:15:00 提供 Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

01 11 2022 07:00:02 提供 Nasdaq GlobeNewswire

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer

12 10 2022 07:00:01 提供 Nasdaq GlobeNewswire

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

11 10 2022 07:00:02 提供 Nasdaq GlobeNewswire

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

28 9 2022 07:00:00 提供 Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

06 9 2022 15:15:00 提供 Nasdaq GlobeNewswire

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

11 8 2022 15:15:00 提供 Nasdaq GlobeNewswire

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

10 6 2022 07:00:00 提供 Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

01 6 2022 07:00:01 提供 Nasdaq GlobeNewswire

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

12 5 2022 15:15:00 提供 Nasdaq GlobeNewswire

Vor to Participate in Two Upcoming Investor Conferences

05 5 2022 07:00:04 提供 Nasdaq GlobeNewswire

Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

25 4 2022 07:00:01 提供 Nasdaq GlobeNewswire